We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Pharm Gp | OXP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.50 |
| Top Posts |
|---|
Posted at 08/3/2018 11:59 by mctmct Has any OXP shareholder received any shares in OPL? I haven't and my stockbroker says that other brokers haven't either. It looks as though the corporate action was mishandled because the capital reorganisation, demerger and name change all came close together. I suggest that all OXP shareholders (now ABA shareholders) chase their brokers to locate their shares in OPL and let this BB know what they discover. |
Posted at 20/11/2017 08:25 by timbo003 >>>>Nick RubensI would assume that if and when they de-merge, shareholders will get one share in each de-merged company for each share they currently own in OXP. Shareholders shouldn't have a problem with that, especially Woodford, as much of his life science SME portfolio is unquoted anyway. Today's news is of interest as it shows that not all EU regulators think alike. I don't think it really makes a lot of difference though, basically it gives them a route to market in Sweden and possibly elsewhere for a chewable or liquid taste mask formula with identical claims to Nurofen and generic ibuprofen tablets, i.e. there would be no claims differentiation and no claims regarding improved safety. However, it would be a relatively straightforward application requiring just the normal pharmaceutics package plus biostudy. |
Posted at 21/3/2017 08:47 by fillipe OXP has moved up quite a % bit in the last week. Looks quite strongish to me, with a 100k lot taken at 3.03p just this minute.f |
Posted at 08/2/2017 09:38 by donald trumpton This is just how OXP moves don't you know. |
Posted at 07/2/2017 10:58 by cpap man Yes barnetpeter but with a bowl comes a cup & handle formation!So a pull back in the OXP share price in the very short term but all of this of course bodes really well for the medium to long term! |
Posted at 17/11/2016 14:56 by tidy 2 Only 30% OXP stock in public hands. Now at 1.9p to buy |
Posted at 17/11/2016 14:53 by tidy 2 #Oxp now £1 mill below cash value!!! |
Posted at 07/9/2016 15:52 by fillipe A good lunch and change of strategy!I still see nothing attractive here, except the cash pile - plus there must be some large investors who who are feeling more than a little of the cold dampness of the malcontent. A new broom and change of direction may be called for at OXP, in which case "better in than out" - hence I've taken a good number at a touch under the 3p, seemingly in common with other trades. Others will have their own reasons, but mine is a straight punt on changes being rung here and a resumption of at least the prospect of better things to come. On the other hand, no changes may well mean an end to my good lunches. gla f |
Posted at 21/7/2016 12:18 by kingcashbilly Beaufort also covered OXP this morning in their morning note:"The announcement was rather shocking. The result reminded us that big pharma, especially those providing OTC medicines, are extremely difficult to please. The feedback from the targeted OTC companies requesting Oxford Pharmascience to further develop its assets for more clarity on regulatory product approval pathways, suggests the platform licence deal is now extended to its longer-term vision. Resignation from its NED, Anand Sharma, ex- Reckitt Benckiser, who only been appointed back at end-February 2016, further undermines confidence. Commercialisation for OXPzero taste masking technology will now clearly take longer. Beaufort regarded reduced GI side effects as most significant benefit of the OXPzero technology and in the absence of any near-term excitement, we downgrade the shares from Speculative Buy to Hold. More positively, the Company remain cash rich as at 30 June 2016 with c.£22.1m (before Research and Development tax credit of £0.74m) in the bank, which enable management to seek further development potential." |
Posted at 27/3/2015 08:51 by doodlebug4 RNS Number : 6350IOxford Pharmascience Group PLC 27 March 2015 Successful Pilot Clinical Study of Immediate Release OXPzero(TM) Naproxen Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that the pilot comparative pharmacokinetics ("PK") study of OXPzero(TM) Naproxen ("OXP 005"), which commenced on 5 March, has been successful and the headline data from the trial demonstrates bioequivalence of OXP005 to Naprosyn(R) (generic naproxen). OXPzero(TM) Naproxen aims to deliver 250mg of reduced gastric irritation naproxen via the Company's patent protected OXPzero(TM) technology in an immediate release oral formulation in order to provide a significantly reduced gastrointestinal (GI) side effect profile compared to standard naproxen tablets. The headline PK data showed results which demonstrate bioequivalence and that the OXPzero(TM)technolog Full results of the study will be published in the following weeks. Based on this data, the company will now progress to a proof of concept endoscopy study to demonstrate the reduced GI irritation benefit of OXPzero(TM) Naproxen, as was previously demonstrated for OXPzero(TM) Ibuprofen in an earlier formulation. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of drugs, with combined annual sales in excess of $12 billion and more than 30 million users worldwide consuming NSAIDs each day (source: Evaluate Pharma). Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero(TM) platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen, diclofenac and aspirin. Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience commented: "Demonstrating the bioequivalence of immediate release OXPzero(TM) Naproxen is a great result and a significant milestone for Oxford Pharmascience. This allows us to proceed with confidence to the endoscopy trial to demonstrate the reduced gastric irritation benefit of OXPzero(TM) Naproxen, and also confirms that the technology has been successfully optimised to achieve immediate and complete drug release. Oxford Pharmascience will now continue to progress confidently with our clinical programmes for both OXPzero(TM) Naproxen and OXPzero(TM) Ibuprofen." Further information about the study: The randomised pilot PK study, which was conducted by Quotient Clinical in the UK, was a single-dose, two arm study between OXPzero(TM) Naproxen and the reference Naprosyn(R) 250mg tablets with ten subjects in each arm. Headline PK data show mean AUC (Area Under the Curve or total drug exposure over time) and mean C(max) (maximum serum concentration) results meet the bioequivalence criteria, demonstrating that the OXPzero(TM) technology has been successfully optimised to enable immediate and complete drug release. Further details about the study can be found at www.ClinicalTrials.g |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
